Micronized Fenofibrate in Dyslipidemia: A Focus on Plasma High-Density Lipoprotein Cholesterol (HDL-C) Levels

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.2, Iss.2, 2002-02, pp. : 125-132

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality

Current Pharmaceutical Design, Vol. 19, Iss. 21, 2013-06 ,pp. : 3841-3857

Bentham Science Publishers

Access to resources Recommend Favorite

Should We Take High-Density Lipoprotein Cholesterol Levels at Face Value?

By > >

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 1, 2010-02 ,pp. : 1-3

Adis International

Access to resources Recommend Favorite

Potential therapeutic agents that raise high-density lipoprotein cholesterol levels

By Rodriguez Annabelle Doshi Rajiv R

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 2, 2003-02 ,pp. : 167-175

Informa Healthcare

Access to resources Recommend Favorite

Paradoxically, serum HDL-cholesterol levels are lowered by concomitant treatment with fenofibrate and rosiglitazone

Reactions Weekly, Vol. 1, Iss. 1019, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Fenofibrate/rosiglitazone interaction: Decreased HDL cholesterol levels: 3 patients

Reactions Weekly, Vol. 1, Iss. 1223, 2008-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite